<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Hammill JA</submitter><funding>John Bienenstock Chair in Molecular Medicine</funding><funding>Canadian Cancer Society</funding><funding>Canadian Research Chair in Translational Immunology</funding><pagination>278-292</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC7191649</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>17</volume><pubmed_abstract>Tumor-targeted chimeric antigen receptor (CAR)-engineered T lymphocytes (CAR-T cells) have demonstrated striking clinical success, but their use has been associated with a constellation of toxicities. A better understanding of the pathogenesis of these toxicities is required to improve the safety profile of CAR-T cells. Herein, we describe a xenograft model of off-tumor CAR-T cell-associated toxicity. Human CAR-T cells targeted against HER2 using a small-protein binding domain induced acute, dose-dependent toxicities in mice. The inclusion of a CD28 or 4-1BB co-stimulatory domain in the CAR was required to produce toxicity; however, co-stimulation through CD28 was most toxic on a per-cell basis. CAR-T cell activation in the lungs and heart was associated with a systemic cytokine storm. The</pubmed_abstract><journal>Molecular therapy oncolytics</journal><pubmed_title>A Cross-Reactive Small Protein Binding Domain Provides a Model to Study Off-Tumor CAR-T Cell Toxicity.</pubmed_title><pmcid>PMC7191649</pmcid><funding_grant_id>313416</funding_grant_id><funding_grant_id>313397</funding_grant_id><pubmed_authors>Milne K</pubmed_authors><pubmed_authors>Bramson JL</pubmed_authors><pubmed_authors>Lau VWC</pubmed_authors><pubmed_authors>Denisova GF</pubmed_authors><pubmed_authors>Dvorkin-Gheva A</pubmed_authors><pubmed_authors>Baker C</pubmed_authors><pubmed_authors>Hammill JA</pubmed_authors><pubmed_authors>Aarts C</pubmed_authors><pubmed_authors>Derocher H</pubmed_authors><pubmed_authors>Kwiecien JM</pubmed_authors><pubmed_authors>Nelson BH</pubmed_authors><pubmed_authors>Heslen CW</pubmed_authors><pubmed_authors>Wu Y</pubmed_authors><pubmed_authors>Bezverbnaya K</pubmed_authors></additional><is_claimable>false</is_claimable><name>A Cross-Reactive Small Protein Binding Domain Provides a Model to Study Off-Tumor CAR-T Cell Toxicity.</name><description>Tumor-targeted chimeric antigen receptor (CAR)-engineered T lymphocytes (CAR-T cells) have demonstrated striking clinical success, but their use has been associated with a constellation of toxicities. A better understanding of the pathogenesis of these toxicities is required to improve the safety profile of CAR-T cells. Herein, we describe a xenograft model of off-tumor CAR-T cell-associated toxicity. Human CAR-T cells targeted against HER2 using a small-protein binding domain induced acute, dose-dependent toxicities in mice. The inclusion of a CD28 or 4-1BB co-stimulatory domain in the CAR was required to produce toxicity; however, co-stimulation through CD28 was most toxic on a per-cell basis. CAR-T cell activation in the lungs and heart was associated with a systemic cytokine storm. The</description><dates><release>2020-01-01T00:00:00Z</release><publication>2020 Jun</publication><modification>2026-05-07T03:16:21.76Z</modification><creation>2020-05-22T19:18:25Z</creation></dates><accession>S-EPMC7191649</accession><cross_references><pubmed>32368616</pubmed><doi>10.1016/j.omto.2020.04.001</doi></cross_references></HashMap>